Funds Flexing 60/40 Playbook Become Investor Favorites in India
Indian funds that offer built-in diversification by combining stocks with assets such as bonds and gold lured in more money than pure equity ones last month for the first time in a year, pointing toward a potential long-term investment shift.
The so-called hybrid plans attracted a net 208 billion rupees ($2.4 billion) of inflows in May, while stock funds garnered just 190 billion rupees, according to data from the Association of Mutual Funds in India. The switch comes as global geopolitical turmoil escalates and Indian equities trail their worldwide peers amid concern over weaker earnings growth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Jefferies Maintains a Buy on Avantor (AVTR) With a $20 PT
Avantor, Inc. (NYSE:AVTR) is one of the . In a report released on June 9, Tycho Peterson from Jefferies maintained a Buy rating on Avantor, Inc. (NYSE:AVTR) with a price target of $20.00. The company's fiscal Q1 2025 results reflected a continued focus on cost management amid concerns about the dynamic macroenvironment, along with disciplined execution. A team of scientists working together to develop a new lab product or process. Net income for the quarter reached $64.5 million, while adjusted EBITDA was $269.5 million. Avantor, Inc. (NYSE:AVTR) also reported an expansion in its cost transformation initiative and anticipates $400 million in gross run-rate savings by the end of 2027. Avantor, Inc. (NYSE:AVTR) is a life sciences tools company that provides mission-critical services and products to the advanced technology and life sciences industries. The company's portfolio includes education and government, biopharma, healthcare, and applied materials and advanced technologies industries. While we acknowledge the potential of AVTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
If You Invested $10K In Rexford Industrial Realty Stock 10 Years Ago, How Much Would You Have Now?
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Rexford Industrial Realty Inc. (NYSE:REXR) is a real estate investment trust focused on infill Southern California industrial properties. It is set to report its Q2 2025 earnings on July 16. Wall Street analysts expect the company to post EPS of $0.58, down from $0.60 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $251.72 million, up from $232.97 million a year earlier. Don't Miss: GoSun's breakthrough rooftop EV charger already has 2,000+ units reserved — become an investor in this $41.3M clean energy brand today. Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. The company's stock traded at approximately $14.89 per share 10 years ago. If you had invested $10,000, you could have bought roughly 672 shares. Currently, shares trade at $36.95, meaning your investment's value could have grown to $24,815 from stock price appreciation alone. However, Rexford Industrial Realty also paid dividends during these 10 years. Rexford Industrial Realty's dividend yield is currently 4.65%. Over the last 10 years, it has paid about $10.06 in dividends per share, which means you could have made $6,756 from dividends alone. Summing up $24,815 and $6,756, we end up with the final value of your investment, which is $31,571. This is how much you could have made if you had invested $10,000 in Rexford Industrial Realty stock 10 years ago. This means a total return of 215.71%. However, this figure is less than the S&P 500 total return for the same period, which was 241.45%. Trending: This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, with minimum investments as low as $100. Rexford Industrial Realty has a consensus rating of "Neutral" and a price target of $45.50 based on the ratings of 14 analysts. The price target implies a more than 23% potential upside from the current stock price. The company on April 16 announced its Q1 2025 earnings, posting FFO of $0.62, compared to the consensus estimate of $0.58, and revenues of $248.82 million, compared to the consensus of $244.74 million, as reported by Benzinga. 'Rexford Industrial delivered solid first quarter performance, underscoring the strength of our platform and the discipline of our execution,' said co-CEOs Howard Schwimmer and Michael Frankel. 'Our differentiated business model and investment-grade balance sheet will continue to afford us the ability to unlock substantial embedded growth and drive long-term shareholder value, while navigating current macroeconomic uncertainty.' For its full-year 2025, the company expects core FFO per diluted share in the range of $2.37 to $2.41. Given the expected upside potential, growth-focused investors may find Rexford Industrial Realty stock attractive. Furthermore, they can benefit from the company's solid dividend yield of 4.65% and consistent hikes. Rexford Industrial Realty has raised its dividend consecutively for the last 10 years. Check out this article by Benzinga for three more stocks offering high dividend yields. See Next: $100k in assets? Maximize your retirement and cut down on taxes: Book your free call with a financial advisor to start your financial journey – no cost, no obligation. Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's how you can earn passive income with just $100. This article If You Invested $10K In Rexford Industrial Realty Stock 10 Years Ago, How Much Would You Have Now? originally appeared on
Yahoo
44 minutes ago
- Yahoo
Asian Value Stocks Estimated Below Intrinsic Worth For June 2025
As global markets navigate a period of economic uncertainty, with the Federal Reserve maintaining interest rates and China's mixed data influencing investor sentiment, Asia's stock markets present intriguing opportunities for value-seeking investors. In this context, identifying stocks that are estimated to be trading below their intrinsic worth becomes crucial, as these may offer potential resilience and growth amid the current market conditions. Name Current Price Fair Value (Est) Discount (Est) Wenzhou Yihua Connector (SZSE:002897) CN¥37.97 CN¥75.92 50% Shenzhen KSTAR Science and Technology (SZSE:002518) CN¥22.15 CN¥43.42 49% Shanghai OPM Biosciences (SHSE:688293) CN¥39.38 CN¥77.60 49.3% Livero (TSE:9245) ¥1707.00 ¥3385.31 49.6% J&T Global Express (SEHK:1519) HK$6.71 HK$13.31 49.6% Heartland Group Holdings (NZSE:HGH) NZ$0.78 NZ$1.55 49.8% GCH Technology (SHSE:688625) CN¥30.39 CN¥60.29 49.6% Forum Engineering (TSE:7088) ¥1202.00 ¥2380.32 49.5% Darbond Technology (SHSE:688035) CN¥39.80 CN¥78.05 49% China Kings Resources GroupLtd (SHSE:603505) CN¥21.36 CN¥42.56 49.8% Click here to see the full list of 284 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We're going to check out a few of the best picks from our screener tool. Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on researching and developing drugs for central nervous system disorders, with a market cap of ₩7.20 trillion. Operations: The company's revenue primarily comes from its New Pharmaceutical Business, amounting to approximately ₩578 billion. Estimated Discount To Fair Value: 47.8% SK Biopharmaceuticals is trading at ₩91,900, significantly below its estimated fair value of ₩176,112.28. Despite a high level of non-cash earnings, the company shows strong cash flow potential with revenue expected to grow 22.6% annually, outpacing the Korean market's 6.8%. While earnings growth at 18% per year lags behind the market's 21.2%, recent profitability and a robust return on equity forecast enhance its investment appeal. Our comprehensive growth report raises the possibility that SK Biopharmaceuticals is poised for substantial financial growth. Delve into the full analysis health report here for a deeper understanding of SK Biopharmaceuticals. Overview: Tonghua Dongbao Pharmaceutical Co., Ltd. is a Chinese company that focuses on the research, development, manufacturing, and sale of pharmaceuticals for diabetes, endocrine, cardiovascular, and cerebrovascular diseases with a market cap of CN¥15.68 billion. Operations: Tonghua Dongbao Pharmaceutical generates revenue primarily from its pharmaceutical products aimed at treating diabetes, endocrine disorders, and cardiovascular and cerebrovascular diseases in China. Estimated Discount To Fair Value: 43.7% Tonghua Dongbao Pharmaceutical is trading at CN¥8.07, significantly below its estimated fair value of CN¥14.33, suggesting it may be undervalued based on cash flows. The company is forecast to achieve profitability within three years with a projected earnings growth rate of 60.47% annually, outpacing the Chinese market's revenue growth of 12.4%. However, its dividend yield of 3.1% lacks coverage by earnings or free cash flows, and return on equity remains modest at 11.8%. Our expertly prepared growth report on Tonghua Dongbao Pharmaceutical implies its future financial outlook may be stronger than recent results. Click here to discover the nuances of Tonghua Dongbao Pharmaceutical with our detailed financial health report. Overview: Alexander Marine Co., Ltd. designs, manufactures, and sells yachts across Taiwan, Europe, Australia, and the United States with a market cap of NT$17.15 billion. Operations: The company's revenue is primarily derived from its yacht manufacturing, processing, and trading business, which generated NT$4.07 billion. Estimated Discount To Fair Value: 38.7% Alexander Marine, trading at NT$182.5, is significantly below its fair value estimate of NT$297.7, potentially making it undervalued based on cash flows. Forecasted earnings growth of 48.55% annually surpasses the Taiwanese market's 13.9%. However, recent financials show a decline in sales and net income compared to last year, with profit margins dropping from 30.5% to 11.4%. The dividend yield of 2.74% is not adequately supported by earnings or free cash flow. Our growth report here indicates Alexander Marine may be poised for an improving outlook. Navigate through the intricacies of Alexander Marine with our comprehensive financial health report here. Dive into all 284 of the Undervalued Asian Stocks Based On Cash Flows we have identified here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A326030 SHSE:600867 and TWSE:8478. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
